These findings underscore the critical role of aberrant internal m7G mRNA modifications in EGFR-TKIs resistance and suggest that targeting the METTL1/WDR4–SCLT1–NF-κB axis may provide a potential therapeutic strategy to overcome drug resistance in NSCLC. This evidence concerns the gene METTL1 and non-small cell lung carcinoma.